Simultaneous assessment of pharmacokinetics of pilsicainide transdermal patch and its electropharmacological effects on atria of chronic atrioventricular block dogs

Journal of Pharmacological Sciences

Volumn 110, Issue 3, 2009, Pages 410-414

  Iwasaki, Hiroshi ^a   Takahara, Akira ^a   Nakamura, Yuji ^a   Satoh, Yoshioki ^a   Nagai, Takeshi ^b   Shinkai, Norihiro ^b   Sugiyama, Atsushi ^a,c  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b Nipro Corporation   (Japan)

^c Yamanashi Research Center of Clinical Pharmacology   (Japan)

Author keywords

Atrial fibrillation; Pilsicainide; Transdermal delivery

Indexed keywords

PILSICAINIDE;

ARTICLE; BLOOD PRESSURE; DRUG BLOOD LEVEL; DRUG EFFECT; ELECTROCARDIOGRAPHY; EXPERIMENTAL DOG; HEART ATRIUM FIBRILLATION; MAXIMUM PLASMA CONCENTRATION; NONHUMAN;

EID: 67749106320     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.09061SC     Document Type: Article

References (15)

1. Kumagai K, Nakashima H, Tojo H, Yasuda T, Noguchi H, Matsumoto N, et al. Pilsicainide for atrial fibrillation. Drugs. 2006;66:2067-2073.
2. Atarashi H, Inoue H, Hiejima K, Hayakawa H. Conversion of recent-onset atrial fibrillation by a single oral dose of pilsicainide (Pilsicainide Suppression Trial on atrial fibrillation). The PSTAF Investigators. Am J Cardiol. 1996;78:694-697. (Pubitemid 126658632)
3. Kanemoto M, Shimizu A, Yamagata T, Esato M, Ueyama T, Yoshiga Y, et al. Differentiation of the electrophysiological effects on the atrial myocardium between the pure Na channel blocker, pilsicainide, and flecainide. Cardiovasc Drugs Ther. 2004;18:295-303. (Pubitemid 39222171)
4. + channel blocker pilsicainide on the electrophysiologic properties of pulmonary veins in patients with atrial fibrillation. J Cardiovasc Electrophysiol. 2004;15:1396-1401.
5. Hashimoto K, Haruno A, Matsuzaki T, Sugiyama A, Akiyama K. Effects of antiarrhythmic drugs on canine ventricular arrhythmia models: which electrophysiological characteristics of drugs are related to their effectiveness? Cardiovasc Drugs Ther. 1991;5 Suppl 4:805-817.
6. Sugiyama A, Takahara A, Honsho S, Nakamura Y, Hashimoto K. A simple in vivo atrial fibrillation model of rat induced by transesophageal atrial burst pacing. J Pharmacol Sci. 2005;98: 315-318. (Pubitemid 41296413)
7. Yokota M, Toyama J, Ukai M, Miyahara T, Koide M, Kato R, et al. Pharmacokinetics and pharmacodynamics of class I antiarrhythmic agents after a single oral administration. Jpn Circ J. 1992;56 Suppl 5:1480-1484.
8. Wang K, Takahara A, Nakamura Y, Aonuma K, Matsumoto M, Sugiyama A. In vivo electropharmacological effects of amiodarone and candesartan on atria of chronic atrioventricular block dogs. J Pharmacol Sci. 2007;103:207-213.
9. Sugiyama A, Ishida Y, Satoh Y, Aoki S, Hori M, Akie Y, et al. Electrophysiological, anatomical and histological remodeling of the heart to AV block enhances susceptibility to arrhythmogenic effects of QT-prolonging drugs. Jpn J Pharmacol. 2002;88:341-350. (Pubitemid 34302986)
10. Takahara A, Sugiyama A, Satoh Y, Iwasaki H, Nakamura Y, Hashimoto K. Cardiovascular profile of the canine torsades de pointes arrhythmia model assessed by echocardiographic and haemodynamic methods. Basic Clin Pharmacol Toxicol. 2007; 101:35-40. (Pubitemid 46934647)
11. Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibrilla- tion by heart failure in dogs: atrial remodeling of a different sort. Circulation. 1999;100:87-95. (Pubitemid 29297945)
12. Sugiyama A. Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts. Br J Pharmacol. 2008;154: 1528-1537.
13. Finnin BC, Morgan TM. Transdermal penetration enhancers: applications, limitations, and potential. J Pharm Sci. 1999;88: 955-958. (Pubitemid 29480582)
14. Aisaka K, Hidaka T, Hattori Y, Inomata N, Ishihara T, Satoh F. General pharmacological studies on N-(2,6-dimethylphenyl)-8-pyrrolizidineacetamide hydrochloride hemihydrate. 3rd communication: effect on cardiovascular system. Arzneimittelforschung. 1988;38:1417-1425.
15. Sakai R, Inoue D, Ishibashi K, Inoue M, Shirayama T, Yamahara Y, et al. Kinetics of frequency-dependent conduction delay by class I antiarrhythmic drugs in human atrium. J Cardiovasc Pharmacol. 1995;25:953-960.